Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Hirschberg, Kristóf [VerfasserIn]   i
 Tarcea, Valentin [VerfasserIn]   i
 Mambou Kamdem Gwanmesia, Patricia Neh [VerfasserIn]   i
 Korkmaz-İçöz, Sevil [VerfasserIn]   i
 Radovits, Tamás [VerfasserIn]   i
 Loganathan, Sivakkanan [VerfasserIn]   i
 Karck, Matthias [VerfasserIn]   i
 Szabó, Gábor [VerfasserIn]   i
Titel:Cinaciguat prevents neointima formation after arterial injury by decreasing vascular smooth muscle cell migration and proliferation
Verf.angabe:K. Hirschberg, V. Tarcea, Sz. Páli, E. Barnucz, P.N. Gwanmesia, S. Korkmaz, T. Radovits, S. Loganathan, B. Merkely, M. Karck, G. Szabó
Jahr:2013
Jahr des Originals:2012
Umfang:8 S.
Fussnoten:Gesehen am 12.07.2018 ; Available online 20 February 2012
Titel Quelle:Enthalten in: International journal of cardiology
Ort Quelle:Amsterdam [u.a.] : Elsevier Science, 1981
Jahr Quelle:2013
Band/Heft Quelle:167(2013), 2, Seite 470-477
ISSN Quelle:1874-1754
Abstract:Aims: Vascular smooth muscle cell (VSMC) migration, proliferation and remodeling of the extracellular matrix contribute to lumen loss after arterial injury leading to restenosis. Several studies indicated the role of the cyclic guanosine monophosphate signaling in neointimal formation. Cinaciguat, the novel soluble guanylate cyclase activator, currently being in phase IIb clinical trial, has been shown to exert antiplatelet and anti-remodeling effects in animal models of vascular pathology. In this study we investigated the effects of cinaciguat on post-injury arterial stenosis. Methods and Results: Male Sprague-Dawley rats (n=100) underwent endothelial denudation by wire injury of the right common carotid artery. Cinaciguat (10mg/kg/day orally) were administered to 50 rats (1-, 2-, 3-day and 1-, 3-week treatment time), while 50 rats received placebo. A 3-week treatment resulted in a significantly reduced vascular stenosis (17.53±10.84% in the treatment group vs. 43.25±30.83% in the control wire injury group) and neointima/media area ratio (0.45±0.32 in the treatment group vs. 1.09±0.69 in the control wire injury group). By using quantitative real-time PCR, Western blot and immunohistochemistry, matrix-metallopreoteinase-9 (MMP-9) was found to be upregulated in the control-injured carotids over the whole follow-up, and cinaciguat significantly decreased MMP-9 expression by 3weeks. As assessed by protein immunoblot, injury-induced local decrease of soluble guanylate cyclase β1 subunit could be recovered by cinaciguat. In vitro wound healing assay with VSMCs revealed dose-dependent antimigratory and antiproliferative effects of cinaciguat. Plasma level of cyclic guanosine monophosphate was significantly elevated after 3weeks of treatment. Conclusion: Our results show that cinaciguat prevents injury-induced neointimal hyperplasia by decreasing VSMC migration and proliferation through the regulation of MMP-9.
DOI:doi:10.1016/j.ijcard.2012.01.032
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: http://dx.doi.org/10.1016/j.ijcard.2012.01.032
 Volltext: http://www.sciencedirect.com/science/article/pii/S0167527312000502
 DOI: https://doi.org/10.1016/j.ijcard.2012.01.032
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Cinaciguat
 Injury
 Metalloproteinases
 Neointima
 Restenosis
K10plus-PPN:1577536045
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68285000   QR-Code
zum Seitenanfang